Brenda K Mann
Brenda K. Mann, PhD, is Vice President for Research & Development at EyeGate Pharmaceuticals, focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye. She is also a co-founder of Metis Therapeutics, focused on developing products for women’s health, and is an Adjunct Associate Professor in the Department of Bioengineering at the University of Utah. Dr. Mann holds a BS and PhD in chemical engineering from Iowa State University and Rice University, respectively. Brenda has extensive experience with developing hydrogels for tissue engineering, wound healing, and drug delivery applications.
Prior to joining EyeGate, she was VP for R&D at Jade Therapeutics, which was acquired by EyeGate in March 2016. Dr. Mann was a co-founder and VP for R&D at SentrX Animal Care, focused on developing and commercializing veterinary biomaterials, where she developed all of the product lines currently being sold worldwide, as well as several custom products and products now in the development pipeline. Dr. Mann was also a founding faculty member of the Keck Graduate Institute of Applied Life Sciences, where she was the Fletcher Jones Foundation Assistant Professor, and now continues to serve on its Advisory Council. Dr. Mann was formerly a technical advisor at Arnold White & Durkee, an intellectual property law firm, and is a registered patent agent. She is entering her tenth year volunteering as the Director of the Salt Lake Valley Science and Engineering Fair. She also serves on the External Advisory Board for the Department of Bioengineering at the University of Louisville. Dr. Mann received the Rice University Outstanding Woman Award in 1996, the Young Investigator Award from the International Society for Applied Cardiovascular Biology in 2000, and the Teacher Tribute Award from Stanford University in 2015.